The mitochondria-targeting compound PTC299 enhances megakaryocyte and platelet production
Stem Cells Translational Medicine · 18.05.2026 · 15 (7)
DOI: 10.1093/stcltm/szag035 ↗Kurz gefasst
Fachartikel in der Zeitschrift Stem Cells Translational Medicine, online erschienen am 27.06.2026. Verfasst von Xiaoli Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Guizhou Medical University, Gui'an New District, Guiyang 561113, China. Hauptthemen laut MEDLINE: Megakaryocytes, Blood Platelets, Mitochondria, Thrombocytopenia. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Innovative Drug Research and Development National Science and Technology Major Project, National Natural Science Foundation of China.
Abstract (Originalsprache)
Backgroud: Thrombocytopenia is a common complication of various clinical conditions, resulting from impaired megakaryocyte function, reduced platelet production, or excessive platelet destruction. Current treatments, including platelet transfusions and thrombopoietin receptor agonists, are limited by platelet supply constraints and risks such as thrombotic complications. Emerging research highlights the role of mitochondrial-related biological processes or components in thrombopoiesis, yet targeted therapeutics remain scarce.
Methods
In this study, we investigated mitochondria-targeted compounds for their potential to enhance megakaryocyte and platelet productionusing a fetal liver megakaryocyte differentiation and platelet culture system, and explored their effects on in vivo megakaryocyte and platelet production using a radiation damage-induced thrombocytopenia mouse model.
Results
Our findings identify PTC299, a dihydroorotate dehydrogenase and VEGFA mRNA translation inhibitor, as a promising pro-plateletogenic agent. PTC299 not only enhances megakaryocyte and platelet production in vitro but also accelerates their recovery in a mouse model of radiation-induced thrombocytopenia. Additionally, PTC299 alleviates irradiation-induced splenomegaly.
Conclusion
PTC299 promotes megakaryocyte differentiation and platelet generation both in vitro and in vivo, demonstrating potential values for thrombocytopenia treatment and platelet regeneration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Pharmacy, Guizhou Medical University, Gui'an New District, Guiyang 561113, China.
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc…
- Tianjin Institutes of Health Science, Tianjin 301600, China.
- Center for Tissue Engineering and Stem Cell Research, Guizhou Medical University, Gui'an New District, Guiyang 561113, China.
- HaemoCure Inc, Tianjin 300459, China.
ORCID-Profile: Jiaxi Zhou
Förderung
- Innovative Drug Research and Development National Science and Technology Major Project
- National Natural Science Foundation of China
Zitieren
APA
Wang, X., Xia, M., Cai, Y., Huo, Z., Zhong, Y., Su, P., Liu, C., Wang, H., Shen, X., Wang, F., Xu, J., & Zhou, J. (2026). The mitochondria-targeting compound PTC299 enhances megakaryocyte and platelet production. Stem Cells Translational Medicine, 15(7). https://doi.org/10.1093/stcltm/szag035
Vancouver
Wang X, Xia M, Cai Y, Huo Z, Zhong Y, Su P, et al. The mitochondria-targeting compound PTC299 enhances megakaryocyte and platelet production. Stem Cells Translational Medicine. 2026;15(7). doi:10.1093/stcltm/szag035
BibTeX
@article{Wang2026,
author = {Wang, Xiaoli and Xia, Meijuan and Cai, Yifei and Huo, Ziqi and Zhong, Yao and Su, Pei and Liu, Cuicui and Wang, Hongtao and Shen, Xiangchun and Wang, Fei and Xu, Jianwei and Zhou, Jiaxi},
title = {The mitochondria-targeting compound PTC299 enhances megakaryocyte and platelet production},
journal = {Stem Cells Translational Medicine},
year = {2026},
volume = {15},
number = {7},
doi = {10.1093/stcltm/szag035}
}
EUVIMED